dovitinib [cytosol]

Stable Identifier
Locations in the PathwayBrowser
for Species:

A Novartis tyrosine kinase inhibitor with activity against multiple tyrosine kinase receptors including FGFRs, VEGFRs, PDGFRs, KIT, FLT3 and CSFR. TKI258 is in Phase II clinical trials for advanced breast cancer in patients with and without FGFR1 amplification (NCT00958971), for endometrial cancer with WT or activated FGFR2 mutants (NCT01379534), for relapsed myeloma with and without the t4:14 FGFR3 translocation/amplification (NCT01058434), and in bladder cancer in cases where archived material is available to check for correlation with FGFR3 mutation status (NCT00790426).

Literature References
PubMed ID Title Journal Year
15897558 In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models

Aukerman, SL, Garrett, E, Lee, SH, Ye, H, Gelb, AB, Lopes de Menezes, D, Samara, E, Harris, A, Heise, C, Nordahl, L, Vora, J

Clin Cancer Res 2005
18381947 A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors

Garzon, F, Molife, R, Michelson, G, de Bono, JS, Morrison, R, Hardie, M, Heise, C, Aziz, N, Jadayel, D, Judson, IR, Braendle, E, Sarker, D, Butzberger-Zimmerli, P, Louie, S, Evans, TR, Marriott, C, Fox, JA

Clin Cancer Res 2008
External Reference Information
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Cross References
PubChem Compound
Cite Us!